Answers are grounded in this paper and cite their sources.
Patients with hemosiderosis who also suffer from coexistent anemia may be unable to tolerate frequent phlebotomies needed for depletion of body iron stores. Chelation therapy, an alternative approach, may be unsuitable for some patients due to allergic reactions, poor response or intolerance of long-duration subcutaneous administration. The use of recombinant human erythropoietin in such patients could increase the hematocrit and improve exercise tolerance allowing for more frequent phlebotomies. We report the successful use of this combined approach in two such patients.
No takes yet. Share an insight, caveat, or question.
Bilgrami et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: